Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ishares Msci Brazil ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.83 (market cap $39.89B), while Ishares Msci Brazil ETF trades at $35.62. The key difference: Ishares Msci Brazil ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWZ | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $41.75 |
52-Week Low | $278.09 | $26.52 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EWZ trades at $35.93, up 2.77% with a bullish technical signal supported by moving averages. The ETF has gained approximately 11% year-to-date, benefiting from Brazil's monetary easing cycle and commodity strength. Recent news highlights Brazil's $9.92 billion Eco Invest auction and export adjustments to meet EU requirements, supporting economic growth prospects.
Outlook remains positive with asymmetric upside from Brazil's rate-cutting cycle and commodity tailwinds, though concentrated exposure to Petrobras and Vale creates dividend inconsistency risk. The ETF trades at a discount to emerging market peers with 9.6x forward P/E, offering value if Brazil's economic reforms continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
